Lateral Flow Assays Market to Hit USD 12.52 Billion by 2030: Driving the Next Wave of Rapid Diagnostics

Asia-Pacific is the second largest region along with fastest growing region of lateral flow assays market owing to major investments in rapid testing in this region.
The global [https://www.marketsandmarkets.com/Market-Reports/lateral-flow-assay-market-167205133.html] is on a high-growth trajectory, projected to rise from USD 8.51 billion in 2025 to USD 12.52 billion by 2030, registering a robust CAGR of 8.0%. This surge reflects the growing global demand for rapid, affordable, and point-of-care diagnostic testing solutions, fueled by rising infectious disease prevalence, a growing elderly population, and expanding use of home-based testing kits.

By technique, the lateral flow assay kits and reagents market is segmented into competitive, sandwich, and multiplex detection assays. Sandwich assays dominated the market, with a share in 2024. The large share of this segment can be attributed to the better assay sensitivity and specificity associated with sandwich assays and their extensive application in the measurement of critical analytes (such as cardiac and hepatitis markers).

By sample type, the lateral flow assays market is segmented into blood, urine, saliva, and other samples (nasal swabs, throat swabs, and vaginal fluid). Blood samples accounted for the largest market share in 2024. Technological advancements in testing methods have also improved accuracy and reduced turnaround times, making these tests more appealing for both healthcare providers and patients. The extensive use of blood samples in lateral flow tests and the easy detection of disease antibodies from blood samples are the key factors driving the growth of this market segment.

By geography, the lateral flow assays market is segmented into six major segments, namely, North America, Europe, Asia Pacific, Latin America, Middle East & Africa, and GCC Countries. North America accounts for the largest market share in the lateral flow assays market in 2024. North America is the leading region in the lateral flow assays market due to its advanced healthcare infrastructure and significant investments in medical technology innovation. The presence of major medical device manufacturers and growing LFA evolution, leading in smartphone-enabled readers, AI-powered result interpretation, and multiplex testing formats.

Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=167205133 [https://www.marketsandmarkets.com/requestsampleNew.asp?id=167205133&utm_source=abnews&utm_medium=paidpr&utm_campaign=lateralflowassaysmarket]

Prominent players in the lateral flow assays market include Abbott Laboratories (US), F. Hoffman-La Roche Ltd. (Switzerland), Danaher Corporation (US), Becton, Dickinson and Company (US), QuidelOrtho Corporation (US), Siemens AG (Germany), bioMerieux SA (France), Thermo Fisher Scientific, Inc. (US), Revvity, Inc. (US), Hologic Inc. (US), QIAGEN N.V. (Netherlands), Merck KGaA (Germany), Surmodics, Inc. (US), and OraSure Technologies Inc. (US).

Abbott Laboratories (US):

Abbott is the leading player in the global lateral flow assay market, accounting for the largest share of the global LFA market in 2024. Its dominance stems from a diverse LFA portfolio encompassing infectious disease, cardiac, and consumer-based diagnostics, backed by robust continuous innovation. Abbott's strategic investments in reader-enabled and multiplex LFA formats, along with a strong global manufacturing footprint and R&D pipeline, reinforce its leadership position. The company's focus on benchtop reader integration and pharma/biotech QC applications signals its intent to stay ahead in high-value LFA segments, ensuring sustained competitive advantage.

F. Hoffman-La Roche Ltd. (Switzerland)

Roche is a key leader in the lateral flow assay space, accounting for the second-largest share of the global market. Known for its high-sensitivity LFA products, Roche has made strides in digital-read capabilities and advanced sandwich assays targeting infectious diseases and oncology screening. Its regular product refreshes and R&D expansion, including enhanced multiplex LFA formats, reflect its ongoing commitment to innovation. Roche's established global footprint and investment in smart diagnostic technologies position it as a formidable force in premium LFA segments, strengthening its presence during market transitions.

Danaher Corporation (US)

Danaher commands a significant share of the LFA market. Beyond components, its Life Sciences portfolio, bolstered by acquisitions like Pall and Cytiva, equips Danaher to influence next-generation LFA platforms for process development and QC in biopharma. In 2023, Danaher further solidified its position by acquiring Abcam, enhancing capabilities in research-stage diagnostics. With a strong operational backbone, strategic M&A strategy, and growing role in supplying membranes, conjugates, and benchtop instruments, Danaher is a key enabler of LFA innovation, powering the ecosystem behind major LFA brands.

Media Contact
Company Name: MarketsandMarkets Trademark Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=lateral-flow-assays-market-to-hit-usd-1252-billion-by-2030-driving-the-next-wave-of-rapid-diagnostics]
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/lateral-flow-assay-market-167205133.html

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.